Beth Sufian's guide to insurance

Passing along this information: ---- Children and adults with cystic fibrosis (CF) need some form of insurance coverage to help pay for medical care and medications needed to treat the disease. Beth Sufian, the author, has developed a general guide with Gilead Sciences, Inc. to assist people with CF, their families, and healthcare providers in identifying potential health insurance policies offered by an employer, and government programs such as Social Security benefits, Medicaid, Medicare, and state-government programs. In addition, the Affordable Care Act may help people with CF access coverage. To download a copy of the guide, click here. After reading the guide, you may have questions about your ability to access insurance coverage or Social Security benefits. At the end of the guide, you will find a list of additional resources for information. You can also contact the Cystic Fibrosis Legal Hotline or the Cystic Fibrosis Social Security Project at 1-800-622-0385.
Source: Cystic Fibrosis Payment Assistance Resources Forum - Category: Respiratory Medicine Authors: Tags: Payment Assistance Resources Source Type: forums

Related Links:

In this study, it is aimed to restrain its proteolytic activity with K23D mutation, which changes lysine (K) residue at the 23rd position to aspartic acid (D). Because we wanted to produce a hassle-free human recombinant immune reactive trypsinogen proenzyme which has similar antigenic properties with the native form. It is also aimed that the mutant IRTs do not exhibit proteolytic activity for the development of durable detection kits with a longer shelf life for both two isoforms. The innovation was actualized in order to use IRTs as a standard antigen in Immunoassays such as ELISA kits. The gene was synthesized as mutat...
Source: Protein Expression and Purification - Category: Biochemistry Source Type: research
Cystic fibrosis (CF) is a recessive genetic disease resulting from mutations in the CF transmembrane conductance regulator (CFTR) gene. Despite marked improvements in CF treatment, pulmonary disease remains the main cause of morbidity and mortality.
Source: Prostaglandins, Leukotrienes and Essential Fatty Acids - Category: Biomedical Science Authors: Source Type: research
Chronic rhinosinusitis (CRS) is present in up to 100% of patients with cystic fibrosis (CF). CF-associated CRS is particularly recalcitrant, and sinus disease can have important implications in the health of the lower airways and overall quality of life in these patients. Both medical and surgical management play important roles in treating CF-associated CRS, but guidelines are lacking. This review summarizes the current literature on both medical and surgical management of this disease to provide an up-to-date analysis and recommendations on the treatment of CF-associated CRS.
Source: Immunology and Allergy Clinics of North America - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSIONS: Probiotics significantly reduce faecal calprotectin (a marker of intestinal inflammation) in children and adults with CF, however the clinical implications of this require further investigation. Probiotics may make little or no difference to pulmonary exacerbation rates, however, further evidence is required before firm conclusions can be made. Probiotics are associated with a small number of adverse events including vomiting, diarrhoea and allergic reactions. In children and adults with CF, probiotics may be considered by patients and their healthcare providers. Given the variability of probiotic composition ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Authors: Louagé A, Knoop C, Hanssens L Abstract INTRODUCTION: The aim of this study was to evaluate the impact of the transition period from childhood to adulthood in patients with cystic fibrosis (CF) being followed up in our reference center. METHODS: The clinical, functional, inflammatory and microbiological parameters of all transition patients were compared two years before (T-2) and two years after the transfer (T+2) from paediatric to adult centers and further analysed according to whether the transition conditions were optimal or suboptimal. RESULTS: Twenty-eight patients were included. The m...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Pulmonary disease remains the most significant determinant of morbidity and mortality in cystic fibrosis (CF). Patients with CF typically experience progressive decline in lung function punctuated by pulmonary exacerbations [1], acute episodes characterized by worsened cough and sputum production and thickness, as well as decreases in pulmonary function, appetite, and weight. Over 34% of patients with CF are treated with IV antibiotics for an exacerbation each year [2]; median duration of hospitalization for these events is 9.3 days, and the median duration of IV antibiotics is 13 days [2].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research
Autosomal recessive diseases, such as cystic fibrosis (CF), require inheritance of 2 mutated genes. However, some studies indicate that CF carriers are at increased risk for some conditions associated with CF. These investigations focused on single conditions and included small numbers of subjects. Our goal was to determine whether CF...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Biological Sciences Source Type: research
CONCLUSIONS: a PR program induced a pro-oxidative effect accompanied by changes in circulating inflammatory cytokine levels in NCFB patients. Our results would also suggest a possible beneficial effect of the HMB enriched supplement on neutrophil level regulation in these patients. The information provided in this study could be useful for choosing the right therapeutic approach in the management of bronchiectasis. PMID: 31960695 [PubMed - as supplied by publisher]
Source: Nutricion Hospitalaria - Category: Nutrition Authors: Tags: Nutr Hosp Source Type: research
Condition:   Cystic Fibrosis Intervention:   Drug: LUM/IVA Sponsor:   Vertex Pharmaceuticals Incorporated Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
SIX young cystic fibrosis sufferers get their hands on boxes of lifesaving pills at last after fighting in our crusade to win an NHS deal. Last year, all six spoke out in separate, tear-jerking Daily Express stories to plead for the medications produced by US firm Vertex.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
More News: Children | Cystic Fibrosis | Government | Health | Health Insurance | Insurance | Legislation | Medicaid | Medicare | Respiratory Medicine